Virax President and Chief Executive Officer James Foster said, “This is a vital milestone for Virax as we now have the ability to enter the key U. S. market. U. S. COVID-19 remains a primary viral risk and is endemic. We have a giant production capacity (through our component) up to 2 million tests per day that will allow us to serve a giant part of the US market, if needed. We look to the future to keep you informed about distribution contracts as they are signed.
The check is designed for non-public over-the-counter use and for a non-professional adult user to review another user 2 years of age or older in a non-laboratory setting through a nasal swab. The check seeks to identify COVID-19 — related infections with effects to have within 10 minutes. Testing on symptomatic subjects involves a sensitivity of 98. 8% and a specificity of 97. 2%.
Founded in 2013, Virax Biolabs is a cutting-edge biotechnology company focused on the diagnosis and detection of immune responses to viral diseases.
In addition to distributing a variety of viral control kits in unique geographies, Virax Biolabs Group Limited is recently launching a proprietary generation of T-cell control with the aim of offering an immune profiling platform that assesses each individual’s immune threat profile against the world’s leading ones. Viral threats. T-cell verification can be effective in controlling and remedying COVID-19, as well as other threats such as monkeypox, hepatitis B, malaria, herpes, and human papillomavirus. For more information, visit www. viraxbiolabs. com.
This press release includes forward-looking statements. In addition, from time to time, we or our representatives may make oral or written forward-looking statements. We base these forward-looking statements on our expectations and projections about long-term events, which we derive from information recently presented to us. These forward-looking statements relate to long-term events or our long-term performance, including: our monetary performance and projections; our profit and profit growth; and our business customers and opportunities. You can identify forward-looking statements through those that are not old in nature, i. e. , those that use words such as “possibly”, “should”, “expect”, “anticipate”, “intend”, “estimate”, “believe “, “plans”, “projects”, “predicts”, “potential” or “expects” or the negative form of those terms or other similar terms. When comparing these forward-looking statements, you will need to consider a variety of factors, including: our ability to replace the Company’s management; our ability to keep up with new technologies and the needs of the conversion market; and the competitive environment in which our business operates. Others could cause our actual effects to differ materially from any forward-looking statement. Forward-looking statements are predictions only. The forward-looking events discussed in this press release and other statements made from time to time through us or our representatives would not possibly occur, and actual events and effects would be possible. and differ materially and are subject to risks, uncertainties and assumptions about us. We have no legal responsibility to publicly update or revise any forward-looking statement, whether due to uncertainties and assumptions, the forward-looking occasions discussed in this press release and other statements made from time to time by us or our representatives could not possibly . occur. Array
SOURCE Virax Biolabs